BDTX vs GLDG Comparison

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

GoldMining Inc is a mineral exploration company with a focus on the acquisition, exploration, and development of projects in Colombia, Brazil, the United States, Canada, and Peru. Its principal projects are the La Mina Gold project and its Titiribi Gold-Copper project, located in Colombia; the Sao Jorge Gold Project, located in Brazil; and its interest in the Whistler Gold-Copper Project, located in Alaska, United States. Additionally, the company has several other projects in its portfolio, such as the Yellowknife Gold Project, Cachoeira Gold Project, Surubim Gold Project, Yarumalito Gold Project, Rea Uranium Project, etc. The firm has two operating segments, with U.S. GoldMining as one distinct operating segment and all other subsidiaries, or Others, being the second operating segment.